Paroxysmal nocturnal hemoglobinuria

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 02:47, 21 October 2013 by Binunair2002 (talk | contribs) (Created page with "'''Eculizumab''' '''Regimen:''' * Bulleted list item IV 600 mg weekly for 4 doses, followed by 900 mg 1 week later; then 900 mg every 2 weeks as maintenance treatment . ''...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Eculizumab

Regimen:

  • Bulleted list item

IV 600 mg weekly for 4 doses, followed by 900 mg 1 week later; then 900 mg every 2 weeks as maintenance treatment . Supportive medications:

  • Bulleted list item

Meningococcal vaccine at least 2 weeks prior to treatment initiation; may revaccinate per current guidelines

Reference:

1)Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-1243

2)Schubert, J., Hillmen, P., Röth, A., Young, N. S., Elebute, M. O., Szer, J., Gianfaldoni, G., Socié, G., Browne, P., Geller, R., Rother, R. P. and Muus, P. (2008), Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 142: 263–272

3)Hill A, Kelly RJ, Kulasekararaj AG, et al. Eculizumab in paroxysmal nocturnal hemoglobinuria (PNH): a report of all 153 patients treated in the UK. Blood. Vol. 120.(21) 2012. p. 3472

Retrieved from "https://hemonc.org/w/index.php?title=Paroxysmal_nocturnal_hemoglobinuria&oldid=3898"